Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Average Rating of “Buy” from Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has received an average recommendation of “Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $63.25.

SUPN has been the subject of several recent research reports. Bank of America initiated coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $65.00 target price for the company. Cantor Fitzgerald lifted their target price on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 30th. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $40.00 to $65.00 in a research report on Thursday, October 9th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Finally, TD Cowen raised their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd.

Insider Activity

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 14,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $44.51, for a total transaction of $623,140.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares in the company, valued at $689,726.96. The trade was a 47.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the sale, the chief financial officer owned 1,246 shares of the company’s stock, valued at approximately $55,434.54. The trade was a 90.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 362,741 shares of company stock valued at $16,390,592 over the last ninety days. 8.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new stake in Supernus Pharmaceuticals during the first quarter valued at approximately $41,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Supernus Pharmaceuticals during the first quarter valued at approximately $46,000. USA Financial Formulas bought a new stake in Supernus Pharmaceuticals during the third quarter valued at approximately $50,000. EverSource Wealth Advisors LLC bought a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $51,000. Finally, Raymond James Financial Inc. bought a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $55,000.

Supernus Pharmaceuticals Stock Down 2.4%

SUPN opened at $55.13 on Tuesday. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of 47.94 and a beta of 0.78. The firm has a 50-day moving average price of $48.02 and a 200-day moving average price of $38.83. Supernus Pharmaceuticals has a twelve month low of $29.16 and a twelve month high of $57.65.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.